![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 7, 4589-4592, February 15, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
§,
From the
London Regional Cancer Center,
University of Western Ontario, London N6A 4L6, Canada,
¶ Pulmonary and Critical Care Section, Yale University School
of Medicine, New Haven, Connecticut 06520-8057, and
Department
of Medicine, University of California and San Francisco Veterans
Affairs Medical Center, San Francisco, California 94121
In 1979, hyaluronan was demonstrated to bind
specifically and with high affinity to intact cells (1), and in 1980, it was shown to enhance cell motility on two-dimensional culture
surfaces where the hydrodynamic properties of hyaluronan were not
necessary to open spaces for cells to move into (2). These two
demonstrations raised the possibility that hyaluronan had the potential
to directly modify cell behavior. In 1989, hyaluronan was shown to
promote protein tyrosine phosphorylation cascades (3) that were later proven to be required for hyaluronan-mediated motility on planar culture surfaces (4). Since then, small amounts (nanograms) of
hyaluronan have been shown to activate a variety of protein tyrosine
and serine/threonine kinases. These include the non-receptor protein
tyrosine kinase Src (5, 6), HER2/Neu receptor (7), focal adhesion kinase (4, 8-10), protein kinase C (11, 12), and
MAP1 kinases (9, 10). Likely
as a consequence of regulating these kinases, hyaluronan promotes
expression of specific cytokines and proteins involved in extracellular
matrix remodeling (e.g. Ref. 13).
The study of murine cardiac cells derived from hyaluronan synthase 2 (HAS2) knockout mice has provided the most convincing evidence for a
signaling capability of hyaluronan (14). HAS2 The first cell-associated hyaladherin, RHAMM, whose cell
surface form is now designated CD168, was isolated from embryonic heart
cells (16).2 Later CD44 was
identified as the first integral hyaluronan "receptor." Both RHAMM
and CD44 mediate hyaluronan signaling and participate in growth
factor-regulated signaling. However, they likely regulate signaling by
different mechanisms because they are not homologous proteins, are
compartmentalized differently in the cell (17),2 and differ
in the mechanisms by which they bind to hyaluronan (18) (Figs.
1 and 2). Additional cellular
hyaladherins have been identified
(19-22), but their role in cell signaling has not yet been reported.
Therefore, this review focuses upon the signaling cascades that RHAMM
and CD44 regulate.
![]()
INTRODUCTION
TOP
INTRODUCTION
Role of Hyaluronan Receptors...
Potential Role of Hyaluronan...
Role of Hyaladherins in...
Conclusions
REFERENCES
/
cardiac cells do not
undergo an endothelial-mesenchymal transformation associated with
migration from tissue explants whereas wild-type cells do (14).
However, the addition of nanogram amounts of exogenous hyaluronan
"rescues" knockout cells. Furthermore, a dominant negative mutant
of the small GTPase, Ras, blocks the effects of exogenous
hyaluronan (14). These results suggest that hyaluronan signals through
Ras to regulate motility and are consistent with previous studies
showing that exogenous hyaluronan-receptor interactions regulate Ras
signaling (4, 8). This ability of hyaluronan to activate intracellular
signaling cascades requires interactions with cell-associated
hyaluronan-binding proteins or hyaladherins (15) but is additionally
modified by the amount and size of hyaluronan present in the
environment of the cell. Further, not all cell types activate signaling
cascades in response to hyaluronan (11), indicating that cell
background is also an important determinant. Here, we review current
understanding of the mechanisms by which hyaluronan signals.
![]()
Role of Hyaluronan Receptors in Signaling
TOP
INTRODUCTION
Role of Hyaluronan Receptors...
Potential Role of Hyaluronan...
Role of Hyaladherins in...
Conclusions
REFERENCES

View larger version (44K):
[in a new window]
Fig. 1.
A current model for hyaluronan dependent,
CD44-specific signaling pathways. CD44-hyaluronan interactions
promote tyrosine kinase (TK) activity of HER2 and the
non-receptor kinase, Src. Src phosphorylates cortactin, which recruits
it to the cell membrane. CD44-hyaluronan interactions also activate
RHOA and Rac1, and CD44 binds to Tiam1 and Vav2. Hyaluronan
(HA) also promotes the association of CD44 forms with
cytoskeletal proteins such as ankyrin and ERM proteins. Activation of
these signaling pathways together leads to tumor behavior such as
migration and invasion. Our current model suggests that the
close interactions between CD44 and its selected binding partners play
a pivotal role in coordinating "cross-talk" among various
intracellular signaling pathways (e.g. Rho/Ras signaling and
receptor-linked (p185HER2)/non-receptor-linked (c-Src) tyrosine
kinase pathways) leading to the concomitant onset of multiple functions
such as tumor cell adhesion, proliferation/growth, migration, and
invasion. MLC, myosin light chains.

View larger version (32K):
[in a new window]
Fig. 2.
A current model for hyaluronan
(HA)-dependent,
RHAMM-mediated signaling pathways. RHAMM is an itinerant
hyaladherin that occurs in multiple subcellular compartments and that
can also be exported to the extracellular milieu where it binds to the
cell surface. Cell surface RHAMM-hyaluronan interactions regulate
signaling through Ras and Src. Cell surface RHAMM modifies the ability
of the PDGF receptor to activate Erk kinase, a key map kinase involved
in cell motility. Intracellular RHAMM proteins encode multiple kinase
docking and recognition sites, and one intracellular form has been
shown to physically associate with Erk1 kinase. Intracellular forms
also associate with the cytoskeleton, notably interphase and mitotic
spindle microtubules. The ability of intracellular RHAMM forms to
associate with multiple signaling complexes and to associate with the
cytoskeleton suggest that they function as adapter proteins like
vinculin and paxillin. FAK, focal adhesion kinase.
CD44
CD44 is an integral protein that is subject to extensive alternative splicing (23-26). All CD44 isoforms contain a link module hyaluronan-binding site in their extracellular domain (see minireview by Day and Prestwich (18) in this series). The binding of CD44 isoforms to hyaluronan affects cell adhesion to extracellular matrix components and is implicated in the stimulation of aggregation, proliferation, migration, and angiogenesis (23-25, 27, 28). The intracellular domain of CD44 isoforms selectively interacts with cytoskeletal proteins and regulates specific signaling (27). Therefore, CD44 isoforms likely provide a direct association between hyaluronan and the cytoskeleton. The mechanisms by which CD44 achieves this association and the signaling cascades that it regulates are summarized in Fig. 1.
CD44 Interaction with Tyrosine Kinases-- CD44 is tightly coupled with at least two tyrosine kinases, p185HER2 (7) and c-Src kinase (6). CD44 and p185HER2 are physically linked to each other via interchain disulfide bonds; and hyaluronan can stimulate CD44-associated p185HER2 tyrosine kinase activity that leads to increased tumor cell growth (7). The cytoplasmic domain of CD44 binds to c-Src kinase at a single site with high affinity (6, 29). Importantly, hyaluronan interaction with CD44 stimulates c-Src kinase activity, increasing tyrosine phosphorylation of the cytoskeletal protein, cortactin. This attenuates the ability of cortactin to cross-link filamentous actin in vitro (Fig. 1) (6). Most Src family kinases are modified with specific lipids that direct them to subdomains of the cell membrane called "rafts" that have high cholesterol and glycolipid content. The Src kinases, Lck and Fyn, associate with CD44 in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes (29). Thus, direct binding of CD44 to c-Src kinase in the membrane "rafts" may facilitate hyaluronan-mediated stimulation of the catalytic activity of c-Src kinase and induce cytoskeleton-regulated tumor cell migration. Therefore, the binding of hyaluronan to CD44 isoforms, which complex with p185HER2 and c-Src kinase, likely trigger direct "cross-talk" between two tyrosine kinase-linked signaling pathways during tumor progression.
CD44-specific Activation of Rho-like GTPases-- Rho GTPases such as RhoA and Rac1 participate in the interaction between CD44 and cytoskeletal proteins. In particular, RhoA is non-covalently linked to a CD44 alternate isoform (e.g. CD44V3,8-10) in breast tumor cells (30). When complexed with CD44V3, RhoA stimulates Rho kinase (ROK) to phosphorylate several cellular proteins including CD44V3,8-10. This phosphorylation promotes binding of the CD44 variant to ankyrin (Fig. 1). Overexpression of the Rho-binding domain can act as a dominant negative inhibitor of ROK and reverse tumor cell-specific phenotypes (30). Therefore, it has been proposed that CD44v3,8-10 and RhoA-mediated signaling are involved in the up-regulation of ROK and that this is necessary for membrane-cytoskeleton interactions and tumor cell migration during the progression of breast cancers (30).
Binding of hyaluronan to some CD44-expressing cells also activates Rac1 signaling, a pathway known to regulate actin assembly that is associated with membrane ruffling, cellular projections, cell motility, and cell transformation (31, 32). In particular, the cytoplasmic domain of CD44 binds to guanine nucleotide exchange factors such as Tiam1 and Vav2 that have been shown to catalyze the GDP-GTP exchange leading to hyaluronan-mediated tumor cell migration (Fig. 1) (32-34). The fact that both Tiam1-Rac1 activation (31, 33, 34) and RhoA-mediated ROK activity (30) are involved in regulating cytoskeleton function and cell motility in a hyaluronan- and CD44-dependent manner suggests these pathways play a pivotal role in hyaluronan-stimulated CD44 signaling.
CD44 Interaction with the Cytoskeleton-- The first 19 residues of the cytoplasmic domain of CD44 interact with the cytoskeleton membrane linker proteins, ezrin/radixin/moesin (ERM) (32), which contain the KKXn(K/R)K motif for phosphatidylinositol 4,5-bisphosphate (PIP2) binding (35). Mutation of this motif on ezrin results in the loss of the PIP2 requirement for optimal binding of ezrin to CD44 but does not influence the complex formation between ezrin and CD44 (35). These findings suggest that the linkage between ERM and CD44 can form in either a PIP2-dependent or a PIP2-independent manner. An involvement of PIP2 in regulating CD44-ERM interaction during hyaluronan signaling has not yet been reported.
Ankyrin is also a family of membrane-associated cytoskeletal proteins expressed in a variety of biological systems (24, 28). The cytoplasmic domain of CD44 (~70 amino acids) is highly conserved in most of the CD44 isoforms and is directly involved in ankyrin binding (24, 28). Deletion mutation analyses indicate that at least two subregions within the CD44 cytoplasmic domain contribute to the ankyrin binding, namely region I (e.g. the high affinity ankyrin-binding region) and region II (e.g. the regulatory region). In particular, region I (306NGGNGTVEDRKPSEL320 in the mouse CD44 and 304NSGNGAVEDRKPSGL318 in the human CD44) is required for hyaluronan-mediated binding and cell adhesion (24). Furthermore, an ankyrin-binding domain of CD44 isoforms has also been shown to be necessary for oncogenic signaling and tumor cell transformation (27). Recently, fragments of the ankyrin repeat domain and/or the subdomain 2 of ankyrin repeat domain have been identified as an ankyrin-binding region for both CD44 (26) and Tiam1 (32). Overexpression of these ankyrin fragments promotes hyaluronan-dependent and CD44-specific tumor cell migration (33). These observations support the notion that CD44-ankyrin interaction is not only very important for presenting CD44 properly for hyaluronan binding but is also required for cytoskeleton activation during hyaluronan signaling (Fig. 1).
RHAMM
Like CD44, RHAMM is alternatively spliced.2 Truncated RHAMM forms are also expressed in cells following injury (36), in tumors, and in some mutant active Ras-transformed cell lines (9, 37-39). RHAMM distributes into multiple compartments including the cell surface (40),2 cytoskeleton (41), mitochondria (42), and cell nucleus (41, 43). The RHAMM gene does not encode a traditional leader sequence to permit secretion via the traditional Golgi/endoplasmic reticulum export pathway, thus, resembling proteins such as bFGF, HIV Tat protein, the homeobox protein engrailed (44), heat shock proteins (45, 46), and epimorphin (47).
The binding of exogenous hyaluronan to cell surface RHAMM plays a key role in activating signaling cascades, probably as a co-receptor for integral membrane proteins. Although the role(s) of intracellular RHAMM protein forms are not yet known, their ability to associate with kinases (5, 9), calmodulin (41, 42), and the cytoskeleton (41, 43) predicts that they play key roles in cytoskeletal assembly. The presence of intracellular hyaladherins typified by RHAMM also raises the interesting possibility that intracellular hyaluronan (48-50) plays a role in signaling. If so, the separation of cell surface RHAMM from the intracellular RHAMM forms provides the potential for a modular association among hyaluronan, cytoskeleton-signaling complexes, and the cell nucleus (Fig. 2). In this case, hyaladherins such as RHAMM could contribute to the back and forth flow of information between the cell genome and the extracellular environment, a phenomenon that has been termed "dynamic reciprocity" (51). For instance, RHAMM modules could represent a modified version of "inside-outside" signaling characteristic of integrin receptors (52).
RHAMM Interaction with Tyrosine and Serine/Threonine Kinases (see Fig. 2)-- Cell surface RHAMM-hyaluronan interactions mediate activation of the protein tyrosine kinases, Src (5) and focal adhesion kinase (4, 8, 10), as well as Erk kinases (10) and protein kinase C (11, 12). Additionally, cell surface RHAMM is required for activation of Erk kinases through PDGF (9), nerve growth factor (53), and after stretch injury (54). Activation of Src through cell surface RHAMM is transient (5) but is nevertheless required for turnover of lamellae focal adhesions and consequently for RHAMM-regulated cell motility (5). Proteins that are phosphorylated on tyrosine as a result of hyaluronan-RHAMM interactions include paxillin, cortactin, focal adhesion kinase, and the MAP kinases, Erk1 and -2 (10).
RHAMM co-associates with ~20% of total cellular Erk1 kinase (9) and ~10% of total cellular Src (5), as determined by co-immunoprecipitation analyses. Because RHAMM contains recognition sequences for both Src and Erk (MOTIF SCANNER, cansite.bidmc.harvard.edu), it is likely that intracellular RHAMM forms associate directly with these kinases. RHAMM contains multiple SH3- and SH2-binding sites as well as putative phosphoacceptor sites for additional serine/threonine kinases. Intracellular forms may therefore participate in linking kinases together as complexes and/or retaining them within the cytoskeleton and the nucleus.
RHAMM Regulation of Ras GTPase-- Several studies have indicated that RHAMM regulates Ras (4, 5, 8, 9, 37, 55), and this regulation likely involves both cell surface and intracellular RHAMM forms. Cell surface RHAMM is required for random motility (4, 5), progression through the G2M boundary of cell cycle (55), and transformation by oncogenic Ras (8), as determined by antibody blocking and soluble protein competition. Both cell surface and intracellular forms of RHAMM may regulate Ras but at different points along the signaling pathways (e.g. in Fig. 2).
The ability of RHAMM to regulate Ras requires its hyaluronan binding
ability. Thus, mutation of the RHAMM hyaluronan-binding sites blocks
oncogenic Ras-mediated motility and transformation (8). This is
consistent with a requirement for Ras in the hyaluronan-mediated rescue
of HAS2
/
cell motility (14).
RHAMM Interaction with the Cytoskeleton--
Cell surface RHAMM
occurs in cell lamellae and podosomes where it co-distributes with
cortactin.2 Exogenous hyaluronan initially promotes
spreading of cell lamellae and turnover of focal adhesions in
fibroblasts transfected with oncogenic Ras that express cell surface
RHAMM and that are plated onto fibronectin-coated surfaces (4). This
effect of hyaluronan is proposed to act through cell surface RHAMM
because blocking RHAMM antibodies inhibit, whereas agonist RHAMM
antibodies mimic this effect (6, 7). The rapid formation and then
disassembly of focal adhesions precede a hyaluronan-induced increase in
cell motility (4). These effects are possibly mediated, either directly or indirectly, through integrin receptors. For example, cell surface RHAMM co-regulates migration of thymocytes on fibronectin substrata in
concert with the integrin fibronectin receptors,
4
1 or
5
1 (56).
Intracellular RHAMM forms associate with the actin cytoskeleton and both interphase and mitotic spindle microtubules (41). The ability of RHAMM to form coiled coils as well as its limited homology with proteins such as D-CLIP (57) that link microtubules and actin filaments suggests that intracellular RHAMM proteins may connect actin and microtubule cytoskeleton (58). Because an association of RHAMM with several kinases has already been established, it is likely that intracellular RHAMM proteins act as adapter molecules, much like vinculin and paxillin (59, 60) that connect the cytoskeleton to signaling complexes. Transcriptional profiling of the cell cycle progression reveals enhanced expression of both RHAMM and hyaluronan synthase 2 (HAS2) at the G2M boundary (61). These last results and the demonstration that intracellular hyaluronan decorates the mitotic spindle (41) once again raise the possible role of intracellular hyaluronan/RHAMM interactions in signaling.
RHAMM and CD44 can perform separate functions in regulating cell
signaling (10, 38, 62, 63). For instance, CD44, but not cell surface
RHAMM, can mediate adhesion of endothelial cells and thymocytes
to hyaluronan (62) and regulate proliferation (38, 63). In
contrast, cell surface RHAMM, but not CD44, is required for migration
(62, 63). As well, cell surface RHAMM but not CD44 appears to be
essential for activation of protein tyrosine kinase cascades by
endothelial cells responding to hyaluronan (10). Deletion of either
CD44 or RHAMM3 does not
result in embryonic lethality and therefore either these two
hyaladherins share some functions and/or other cellular hyaladherins are able to compensate for the loss of either CD44 or RHAMM. Phenotypes for CD44
/
have been described (Ref. 64 and see below).
| |
Potential Role of Hyaluronan Size in Signaling: Importance in Response to Injury |
|---|
|
|
|---|
In physiologic conditions, hyaluronan is a high average molecular
mass polymer in excess of 106 Da. However, following tissue
injury, hyaluronan fragments of lower molecular mass accumulate. A
potential functional significance for hyaluronan fragments has been
suggested by in vitro studies (e.g. Refs.
65-67). Oligomers of 8-16 disaccharides prepared by enzymatic
digestion of native hyaluronan induce angiogenesis in a chick corneal
assay whereas the native hyaluronan molecules do not (68). Small
amounts of high molecular weight hyaluronan can activate
protein-tyrosine kinase cascades in endothelial cells and
Ras-transformed fibroblasts (4, 10), although at lower levels than
smaller fragments (10). Studies with inflammatory macrophages have
shown that fragmented hyaluronan with an average molecular mass of
250,000 Da, but not native hyaluronan from which it was prepared, can
induce the expression of inflammatory genes (64, 65-69). Similar
results have been shown with renal tubular epithelial cells (70), T-24
carcinoma cells (71), and eosinophils (72). Smaller hyaluronan
oligosaccharides in the 6-20 kDa size range (but not the 250,000 Da or
higher molecular mass hyaluronan) induce inflammatory gene expression
in dendritic cells (73). Controls for excluding contaminating
substances that can be present in even medical grade hyaluronan
preparations are often lacking, as noted in Ref. 75. Nevertheless,
biological relevance is suggested by reports showing that fragmented
hyaluronan that induces inflammatory gene expression in
vitro is in the same size range as hyaluronan that accumulates
under inflammatory conditions in vivo (74). A common theme
appears to be that low (but not high) molecular weight hyaluronan can
initiate gene transcription geared toward cell proliferation and
migration. Generation of hyaluronan fragments under conditions of
inflammation, tumorigenesis, or tissue injury as a result of
hyaluronidases (76) or oxidation (77) may then signal the host that
normal homeostasis has been profoundly disturbed.
| |
Role of Hyaladherins in Hyaluronan Internalization and Host Response to Injury |
|---|
|
|
|---|
Cellular hyaladherins also bind and internalize hyaluronan (1).
Depending on the cell type, the binding affinity and rate of
internalization varies. Elegant studies have recently shown that the
avidity of binding of hyaluronan oligomers to CD44 increases with an
oligomer size of up to 38 sugars (78). Labeled hyaluronan is also
observed in the cytoplasm as a diffuse network and in vesicles,
in lamellae and the nucleus of smooth muscle cells and fibroblasts (49, 50). This unusual pattern of uptake is most obvious
following stimulation of serum-starved 3T3 cells or in subconfluent,
mutant active Ras-transfected fibroblasts. Hyaluronan uptake into these
novel compartments is associated with enhanced cell motility (49).
CD44-deficient mice develop normally but exhibit abnormalities in
hematopoiesis and lymphocyte recirculation (79, 80). Induction of
inflammatory gene expression in response to hyaluronan is observed in
the absence of CD44 in cultures of bone marrow and dendritic cells (73,
81). These data suggest that there are CD44-independent mechanisms for
induction of gene expression by hyaluronan. In contrast, CD44-deficient
mice challenged in models of tissue injury have revealed essential
roles for CD44 in regulating pathogenesis of host injury (82, 83).
Depending on the mechanism of pathogenesis and the predominant cell
types that mediate the host injury, differing effects of CD44 have been observed. In a model of endothelial cell injury mediated by
interleukin-2, CD44-deficient mice were protected from endothelial
injury (82). This protection may be because of a decrease in
interleukin-2-induced lymphocyte-activated killer cell activity.
However, in a model of hepatocellular injury due to administration of
concanavalin A, CD44-deficient mice exhibited enhanced hepatitis (83).
The increased susceptibility to hepatocyte injury correlated with the
observation that T cells from CD44-deficient animals were resistant to
activation-induced cell death. The challenge of future studies will be
to sort out the CD44-dependent as well as the independent
roles in mediating hyaluronan-cell interactions.
| |
Conclusions |
|---|
|
|
|---|
Hyaluronan signaling involves cellular hyaladherins such as CD44
and RHAMM that are selectively coupled with their particular downstream
signaling pathway(s) leading to the onset of
hyaluronan-dependent functions in various cell types and
tissues. A signaling response to hyaluronan may be strongly influenced
by both the size of hyaluronan and the cell background. Additional
studies with defined preparations of hyaluronan of varying size that
utilize hyaladherin null mice are clearly required to sort out the
cellular conditions that permit hyaluronan-mediated signaling.
| |
FOOTNOTES |
|---|
* This minireview will be reprinted in the 2002 Minireview Compendium, which will be available in December, 2002.
§ To whom correspondence should be addressed: London Regional Cancer Center, University of Western Ontario, 790 Commissioners Rd. E., London N6A 4L6, Canada. Tel.: 519-685-8651; Fax: 519-685-8646; E-mail: eva. turley@lrcc.on.ca.
Published, JBC Papers in Press, November 20, 2001, DOI 10.1074/jbc.R100038200
2 E. A. Turley and R. E. Harrison, www.glycoforum.gr.jp.
3 C. Toelg, S. Hamilton, and E. A. Turley, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: MAP, mitogen-activated protein; HAS2, hyaluronan synthase 2; ROK, Rho kinase; ERM, ezrin/radixin/moesin; PIP2, phosphatidylinositol 4,5-bisphosphate; PDGF, platelet-derived growth factor; RHAMM, receptor for hyaluronan-mediated motility.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Underhill, C. B.,
and Toole, B. P.
(1979)
J. Cell Biol.
82,
475-484 |
| 2. | Turley, E. A. (1980) Differentiation 17, 93-103[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Turley, E. A.
(1989)
J. Biol. Chem.
264,
8951-8955 |
| 4. |
Hall, C. L.,
Wang, C.,
Lange, L. A.,
and Turley, E. A.
(1994)
J. Cell Biol.
126,
575-588 |
| 5. | Hall, C. L., Lange, L. A., Prober, D. A., Zhang, S., and Turley, E. A. (1996) Oncogene 13, 2213-2224[Medline] [Order article via Infotrieve] |
| 6. |
Bourguignon, L. Y. W.,
Zhu, H.,
Shao, L.,
and Chen, Y. W.
(2001)
J. Biol. Chem.
276,
7327-7333 |
| 7. |
Bourguignon, L. Y. W.,
Zhu, H. B.,
Chu, A.,
Zhang, L.,
and Hung, M. C.
(1997)
J. Biol. Chem.
272,
27913-27918 |
| 8. | Hall, C. L., Yang, B., Yang, X., Zhang, S., Turley, M., Samuel, S., Lange, L. A., Wang, C., Curpen, G. D., Savani, R. C., Greenberg, A. H., and Turley, E. A. (1995) Cell 82, 19-26[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Zhang, S.,
Chang, M. C.,
Zylka, D.,
Turley, S.,
Harrison, R.,
and Turley, E. A.
(1998)
J. Biol. Chem.
273,
11342-11348 |
| 10. |
Lokeshwar, V. B.,
and Selzer, M. G.
(2000)
J. Biol. Chem.
275,
27641-27649 |
| 11. | Hall, C. L., Collis, L., Lange, L., McNicol, A., Gerrard, J. M., and Turley, E. A. (2001) Matrix Biol. 20, 183-192[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Slevin, M., Krupinski, J., Kumar, S., and Gaffney, J. (1998) Lab. Invest. 78, 987-1003[Medline] [Order article via Infotrieve] |
| 13. |
Horton, M. R.,
McKee, C. M.,
Bao, C.,
Liao, F.,
Farber, J. M.,
Hodge-DuFour, J.,
Pure, E.,
Oliver, B. L.,
Wight, T. M.,
and Noble, P. W.
(1998)
J. Biol. Chem.
273,
35088-35094 |
| 14. | Camenisch, T. D., Spicer, A. P., Brehm-Gibson, T., Biesterfeldt, J., Augustine, M. L., Calabro, A., Jr., Kubalak, S., Klewer, S. E., and McDonald, J. A. (2000) J. Clin. Invest. 106, 349-360[Medline] [Order article via Infotrieve] |
| 15. | Toole, B. P. (1990) Curr. Opin. Cell Biol. 2, 839-844[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Turley, E. A. (1982) Biochem. Biophys. Res. Commun. 108, 1016-1024[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Ponta, H., Wainwright, D., and Herrlich, P. (1998) Int. J. Biochem. Cell Biol. 30, 299-305[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Day, A. J.,
and Prestwich, G. D.
(2001)
J. Biol. Chem
277,
4585-4588 |
| 19. |
Banerji, S., Ni, J.,
Wang, S. X.,
Clasper, S., Su, J.,
Tammi, R.,
Jones, M.,
and Jackson, D. G.
(1999)
J. Cell Biol.
144,
789-801 |
| 20. |
Grammatikakis, N.,
Grammatikakis, A.,
Yoneda, M., Yu, Q.,
Banerjee, S. D.,
and Toole, B. P.
(1995)
J. Biol. Chem.
270,
16198-16205 |
| 21. |
Huang, L.,
Grammatikakis, N.,
Yoneda, M.,
Banerjee, S. D.,
and Toole, B. P.
(2000)
J. Biol. Chem.
275,
29829-29839 |
| 22. | Rao, C. M., Deb, T. B., Gupta, S., and Datta, K. (1997) Biochim. Biophys. Acta 1336, 387-393[Medline] [Order article via Infotrieve] |
| 23. | Lesley, J., Hyman, R., and Kincade, P. (1993) Adv. Immunol. 54, 271-335[Medline] [Order article via Infotrieve] |
| 24. | Bourguignon, L. Y. W. (1996) Curr. Top. Membr. 43, 293-312 |
| 25. |
Bourguignon, L. Y. W.,
Lokeshwar, V. B., He, J.,
Chen, X.,
and Bourguignon, G. J.
(1992)
Mol. Cell. Biol.
12,
4464-4471 |
| 26. |
Screaton, G. R.,
Bell, M. V.,
Jackson, D. G.,
Cornelis, F. B.,
Gerth, U.,
and Bell, J. I.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
12160-12164 |
| 27. | Bourguignon, L. Y. W., Zhu, D., and Zhu, H. (1998) Front. Biosci. 3, 637-649 |
| 28. |
Lokeshwar, V. B.,
Ida, N.,
and Bourguignon, L. Y. W.
(1996)
J. Biol. Chem.
271,
23853-23864 |
| 29. | Bourguignon, L. Y. W., Zhu, H., Shao, L., Zhu, D., and Chen, Y. W. (1999) Cell Motil. Cytoskeleton 43, 269-287[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Oliferenko, S.,
Kaverina, I.,
Small, J. V.,
and Huber, L. A.
(2000)
J. Cell Biol.
148,
1159-1164 |
| 31. | Bretscher, A. (1999) Curr. Opin. Cell Biol. 11, 109-116[CrossRef][Medline] [Order article via Infotrieve] |
| 32. |
Bourguignon, L. Y. W.,
Zhu, H.,
Shao, L.,
and Chen, Y. W.
(2000)
J. Biol. Chem.
275,
1829-1838 |
| 33. |
Bourguignon, L. Y. W.,
Zhu, H.,
Shao, L.,
and Chen, Y. W.
(2000)
J. Cell Biol.
150,
177-191 |
| 34. | Bourguignon, L. Y. W., Zhu, H., Zhou, B., Diedrich, F., Singleton, P. A., and Hung, M.-C. (2001) J. Biol. Chem. 277, 48679-48692 |
| 35. |
Barret, C.,
Roy, C.,
Montcourrier, P.,
Mangeat, P.,
and Niggli, V.
(2000)
J. Cell Biol.
151,
1067-1079 |
| 36. | Savani, R. C., Wang, C., Yang, B., Zhang, S., Kinsella, M. G., Wight, T. N., Stern, R., Nance, D. M., and Turley, E. A. (1995) J. Clin. Invest. 95, 1158-1168 |
| 37. | Wang, C., Thor, A. D., Moore, D. H., II, Zhao, Y., Kerschmann, R., Stern, R., Watson, P. H., and Turley, E. A. (1998) Clin. Cancer Res. 4, 567-576[Abstract] |
| 38. | Ahrens, T., Assmann, V., Fieber, C., Termeer, C., Herrlich, P., Hofmann, M., and Simon, J. C. (2001) J. Invest. Dermatol. 116, 93-101[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Li, H., Guo, L., Li, J. W., Liu, N., Qi, R., and Liu, J. (2000) Int. J. Oncol. 17, 927-932[Medline] [Order article via Infotrieve] |
| 40. |
Crainie, M.,
Belch, A. R.,
Mant, M. J.,
and Pilarski, L. M.
(1999)
Blood
93,
1684-1696 |
| 41. | Assmann, V., Jenkinson, D., Marshall, J. F., and Hart, I. R. (1999) J. Cell Sci. 112, 3943-3954[Abstract] |
| 42. | Lynn, B. D., Turley, E. A., and Nagy, J. I. (2001) J. Neurosci. Res. 65, 6-16[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Entwistle, J., Hall, C. L., and Turley, E. A. (1996) J. Cell. Biochem. 61, 569-577[CrossRef][Medline] [Order article via Infotrieve] |
| 44. | Prochiantz, A. (2000) Curr. Opin. Cell Biol. 12, 400-406[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Binder, R. J., Han, D. K., and Srivastava, P. K. (2000) Nat. Immunol. 1, 151-155[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Sondermann, H., Becker, T., Mayhew, M., Wieland, F., and Hart, F. U. (2000) Biol. Chem. Hoppe-Seyler 381, 1165-1174 |
| 47. |
Hirai, Y.,
Lochter, A.,
Galosy, S.,
Koshida, S.,
Niwa, S.,
and Bissell, M. J.
(1998)
J. Cell Biol.
140,
159-169 |
| 48. | Furukawa, K., and Terayama, H. (1977) Biochim. Biophys. Acta 499, 278-289[Medline] [Order article via Infotrieve] |
| 49. | Collis, L., Hall, C., Lange, L., Ziebell, M., Prestwich, R., and Turley, E. A. (1998) FEBS Lett. 440, 444-449[CrossRef][Medline] [Order article via Infotrieve] |
| 50. |
Evanko, S. P.,
and Wight, T. N.
(1999)
J. Histochem. Cytochem.
47,
1331-1342 |
| 51. | Lelievre, S. A., and Bissell, M. J. (1998) J. Cell. Biochem. 30-31 (suppl.), 250-263[CrossRef] |
| 52. | Liu, S., Calderwood, D. A., and Ginsberg, M. H. (2000) J. Cell Sci. 113F, 3563-3571[Abstract] |
| 53. | Lynn, B. D., Li, X., Cattini, P. A., and Nagy, J. I. (2001) Neurosci. Lett. 306, 49-52[CrossRef][Medline] [Order article via Infotrieve] |
| 54. | Bagli, D. J., Joyner, B. D., Mahoney, S. R., and McCulloch, L. (1999) J. Urol. 162, 832-840[CrossRef][Medline] [Order article via Infotrieve] |
| 55. |
Mohapatra, S.,
Yang, X.,
Wright, J. A.,
Turley, E. A.,
and Greenberg, A. H.
(1996)
J. Exp. Med.
183,
1663-1668 |
| 56. | Gares, S. L., and Pilarski, L. M. (2000) Dev. Immunol. 7, 209-225[Medline] [Order article via Infotrieve] |
| 57. | Akhmanova, A., Hoogenraad, C. C., Drabek, K., Stepanova, T., Dortland, B., Verkerk, T., Vermeulen, W., Burgering, B. M., DeZeeuw, C. I., Grosveld, F., and Galjart, N. (2001) Cell 104, 923-935[CrossRef][Medline] [Order article via Infotrieve] |
| 58. | Assmann, V., Gillett, C. E., Pouson, R., Ryder, K., Hart, J. R., and Hanby, A. M. (2001) J. Pathol. 195, 191-196[CrossRef][Medline] [Order article via Infotrieve] |
| 59. | Turner, C. E. (2000) Nat. Cell Bio. 2, E231-236[CrossRef][Medline] [Order article via Infotrieve] |
| 60. |
Bustelo, X. R.
(2000)
Mol. Cell. Biol.
20,
1461-1477 |
| 61. | Cho, R. J., Huang, M., Campbell, M. J., Dong, H., Steinmetz, L., Sapinoso, L., Hampton, G., Elledge, S. J., Davis, R. W., and Lockhart, D. J. (2001) Nat. Genet. 27, 48-54[Medline] [Order article via Infotrieve] |
| 62. |
Masellis-Smith, A.,
Belch, A. R.,
Mant, M. J.,
Turley, E. A.,
and Pilarski, L. M.
(1996)
Blood
87,
1891-1899 |
| 63. |
Savani, R. C.,
Cao, G.,
Pooler, P. M.,
Zaman, A.,
Zhou, Z.,
and DeLisser, H. M.
(2001)
J. Biol. Chem.
276,
36770-36778 |
| 64. |
Tammi, M.,
Day, A. J.,
and Turley, E. A.
(2001)
J. Biol. Chem.
277,
4581-4584 |
| 65. | Noble, P. W., Lake, F. R., Henson, P. M., and Riches, D. W. (1993) J. Clin. Invest. 91, 2368-2377 |
| 66. |
Hodge-Dufour, J.,
Horton, M. R.,
Burdick, M. D.,
Strieter, R. M.,
Noble, P. W.,
Hunter, C.,
Trinchieri, G.,
and Puré, E.
(1997)
J. Immunol.
159,
2492-2500 |
| 67. |
Horton, M. R.,
Shapiro, S.,
Lowenstein, C. J.,
and Noble, P. W.
(1999)
J. Immunol.
162,
4171-4176 |
| 68. | West, D. C., and Kumar, S. (1989) Exp. Cell Res. 183, 179-196[CrossRef][Medline] [Order article via Infotrieve] |
| 69. | Rooney, P., Kumar, S., Ponting, J., and Wang, M. (1995) Int. J. Cancer 60, 632-636[Medline] [Order article via Infotrieve] |
| 70. | Beck-Schimmer, B., Oetrli, B., Pasch, T., and Wuthrich, R. P. (1998) J. Am. Soc. Nephrol. 9, 2283-2290[Abstract] |
| 71. |
Fitzgerald, K. A.,
Bowie, A. G.,
Skeffington, B. S.,
and O'Neill, L. A.
(2000)
J. Immunol.
164F,
2053-2063 |
| 72. |
Ohkawara, Y.,
Tamura, G.,
Iwasaki, T.,
Tanaka, A.,
Kikuchi, T.,
and Shirato, K.
(2000)
Am. J. Respir. Cell Mol. Biol.
23,
444-451 |
| 73. |
Termeer, C. C.,
Hennies, J.,
Voith, U.,
Ahrens, T.,
Weiss, J. M.,
Prehm, P.,
and Simon, J. C.
(2000)
J. Immunol.
165,
1863-1870 |
| 74. | McKee, C. M., Penno, M. B., Cowman, M., and Noble, P. W. (1996) J. Clin. Invest. 98, 2403-2413[Medline] [Order article via Infotrieve] |
| 75. | Fillon, M. C., and Phillips, N. C. (2001) J. Pharm. Pharmacol. 53, 555-561[CrossRef][Medline] [Order article via Infotrieve] |
| 76. | Csoka, T. B., Frost, G. I., and Stern, R. (1997) Invasion Metastasis 17, 297-311[Medline] [Order article via Infotrieve] |
| 77. |
Uchiyama, H.,
Dobashi, Y.,
Ohkouchi, K.,
and Nagasawa, K.
(1990)
J. Biol. Chem.
265,
7753-7759 |
| 78. |
Lesley, J.,
Hascall, V. C.,
Tammi, M.,
and Hyman, R.
(2000)
J. Biol, Chem.
275,
26967-26975 |
| 79. |
Schmits, R.,
Filmus, J.,
Gerwin, N.,
Senaldi, G.,
Kiefer, F.,
Kundig, T.,
Wakeham, A.,
Shahinian, A.,
Catzavelos, C.,
Rak, J.,
Furlonger, C.,
Zakarian, A.,
Simard, J. J.,
Ohashi, P. S.,
Paige, C. J.,
Guteirrez-Ramos, J. C.,
and Mak, T. W.
(1997)
Blood
90,
2217-2233 |
| 80. | Protin, U., Schweighoffer, T., Jochum, W., and Hilberg, F. (1999) 163, 4917-4923 |
| 81. |
Khaldoyanidi, S.,
Moll, J.,
Karakhanova, S.,
Herrlich, P.,
and Ponta, H.
(1999)
Blood
94,
940-949 |
| 82. |
Rafi-Janajreh, A. Q.,
Chen, D.,
Schmits, R.,
Mak, T. W.,
Grayson, R. L.,
Sponenberg, D. P.,
Nagarkatti, M.,
and Nagarkatti, P. S.
(1999)
J. Immunol.
163,
1619-1627 |
| 83. |
Chen, D.,
McKallip, R. J.,
Zeytun, A., Do, Y.,
Lombard, C.,
Robertson, J. L.,
Mak, T. W.,
Nagarkatti, P. S.,
and Nagarkatti, M.
(2001)
J. Immunol.
166,
5889-5897 |
This article has been cited by other articles:
![]() |
L. Y. W. Bourguignon, K. Peyrollier, W. Xia, and E. Gilad Hyaluronan-CD44 Interaction Activates Stem Cell Marker Nanog, Stat-3-mediated MDR1 Gene Expression, and Ankyrin-regulated Multidrug Efflux in Breast and Ovarian Tumor Cells J. Biol. Chem., June 20, 2008; 283(25): 17635 - 17651. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ahmad, S. Kolli, D.-Q. Li, C. S. de Paiva, S. Pryzborski, I. Dimmick, L. Armstrong, F. C. Figueiredo, and M. Lako A Putative Role for RHAMM/HMMR as a Negative Marker of Stem Cell-Containing Population of Human Limbal Epithelial Cells Stem Cells, June 1, 2008; 26(6): 1609 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Kyosseva, E. N. Harris, and P. H. Weigel The Hyaluronan Receptor for Endocytosis Mediates Hyaluronan-dependent Signal Transduction via Extracellular Signal-regulated Kinases J. Biol. Chem., May 30, 2008; 283(22): 15047 - 15055. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Misra, L. M. Obeid, Y. A. Hannun, S. Minamisawa, F. G. Berger, R. R. Markwald, B. P. Toole, and S. Ghatak Hyaluronan Constitutively Regulates Activation of COX-2-mediated Cell Survival Activity in Intestinal Epithelial and Colon Carcinoma Cells J. Biol. Chem., May 23, 2008; 283(21): 14335 - 14344. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Maxwell, J. McCarthy, and E. Turley Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J. Cell Sci., April 1, 2008; 121(7): 925 - 932. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vigetti, M. Viola, E. Karousou, M. Rizzi, P. Moretto, A. Genasetti, M. Clerici, V. C. Hascall, G. De Luca, and A. Passi Hyaluronan-CD44-ERK1/2 Regulate Human Aortic Smooth Muscle Cell Motility during Aging J. Biol. Chem., February 15, 2008; 283(7): 4448 - 4458. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Poola, J. Abraham, J. J. Marshalleck, Q. Yue, V. B. Lokeshwar, G. Bonney, and R. L. DeWitty Molecular Risk Assessment for Breast Cancer Development in Patients with Ductal Hyperplasias Clin. Cancer Res., February 15, 2008; 14(4): 1274 - 1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Golshani, L. Lopez, V. Estrella, M. Kramer, N. Iida, and V. B. Lokeshwar Hyaluronic Acid Synthase-1 Expression Regulates Bladder Cancer Growth, Invasion, and Angiogenesis through CD44 Cancer Res., January 15, 2008; 68(2): 483 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Koyama, N. Kobayashi, M. Harada, M. Takeoka, Y. Kawai, K. Sano, M. Fujimori, J. Amano, T. Ohhashi, R. Kannagi, et al. Significance of Tumor-Associated Stroma in Promotion of Intratumoral Lymphangiogenesis: Pivotal Role of a Hyaluronan-Rich Tumor Microenvironment Am. J. Pathol., January 1, 2008; 172(1): 179 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Yager, R. A. Kulina, and L. A. Gilman Wound Fluids: A Window Into the Wound Environment? International Journal of Lower Extremity Wounds, December 1, 2007; 6(4): 262 - 272. [Abstract] [PDF] |
||||
![]() |
M. Choudhary, X. Zhang, P. Stojkovic, L. Hyslop, G. Anyfantis, M. Herbert, A. P. Murdoch, M. Stojkovic, and M. Lako Putative Role of Hyaluronan and Its Related Genes, HAS2 and RHAMM, in Human Early Preimplantation Embryogenesis and Embryonic Stem Cell Characterization Stem Cells, December 1, 2007; 25(12): 3045 - 3057. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ramaswamy, C. Dumont, A. C. Cruz, J. R. Muppidi, T. S. Gomez, D. D. Billadeau, V. L. J. Tybulewicz, and R. M. Siegel Cutting Edge: Rac GTPases Sensitize Activated T Cells to Die via Fas J. Immunol., November 15, 2007; 179(10): 6384 - 6388. [Abstract] [Full Text] [PDF] |
||||
![]() |
|